Latest Article
|
Bridging tech and biotech As life science converges with big data and redefines biotech, there are more opportunities for engineers and mathematicians to found life science ventures. How difficult is it to make the transition from tech to biotech?
|
SciCafé
|
Startups on the menu: Atreca
|
Trade Secrets Blog
|
The Bioentrepreneur blog, Trade Secrets, boasts contributors from around the globe, providing regular insight and commentary from those helping build the world's biotechnology sectors.
|
Podcast
|
The new episode of Nature Biotechnology's First Rounders podcast features Colin Goddard, who is the former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.
|
View more articles
|
Advertisement |
 |
|
Advertisement |
 |
|
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department
For print subscription enquiries, please contact our subscription department
For other enquiries, please contact our feedback department
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston |
|
No comments:
Post a Comment